Kedves Kollégák!

Kedves Kollégák!

2025. június 26-án csütörtökön, 15:00-kor lesz a 2025 első félév soron következő, utolsó VKK (Vesetranszplantációs Klinikopatológia Kerekasztal) megbeszélése.

Zoom link a következő félév alkalmaira: https://semmelweis.zoom.us/j/96212122711?pwd=BZjeG6PHekb4jKOYe921VdrVFbqPin.1

Helyszín: Semmelweis Egyetem, Sebészeti Transzplantációs és Gasztroenterológiai Klinika, Baross utca 23-25. magasföldszint Transzplantációs Nefrológia Ambulancia tárgyaló - a helyszín változhat, aki személyesen szeretne részt venni, az kérjük érdeklődjön a szervezőknél. 

Az esemény Oftex akkreditált (24 pont) aneszteziol.intenzív terápia, belgyógyászat, csecsemő- és gyermekgyógyászat, gasztroenterológia, immunológia (képesítés), nefrológia, patológia, radiológia, sebészet szakmák részére. 

A pontjóváírás feltétele legalább 4 alkalommal történő részvétel (összesen 6-ból). 

A mindennapi gyakorlatunk részeként hónapról hónapra elvégzett vesegraft szövettani mintákat közösen értékeljük, és megbeszéljük a kapcsolódó eseteket, továbbá a szakmai aktualitásokról esik szó interdiszciplináris megközelítésben. 

A fórumra várunk minden transzplantáció iránt érdeklődő Kollégát!

Üdvözlettel, 

Cseprekál Orsolya, Dobi Deján, Wágner László, Marton Adrienn

 

 

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation